We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current RARE market cap is 3.58B. The company's latest EPS is USD -6.1533 and P/E is -6.38.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 127.39M | 108.83M | 147.03M | 139.49M | 164.88M |
| Operating Income | -122.05M | -165.35M | -116.36M | -131.99M | -122.28M |
| Net Income | -123.19M | -170.68M | -131.6M | -133.52M | -133.39M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 271.03M | 351.41M | 363.33M | 434.25M | 560.23M |
| Operating Income | -330.12M | -381.74M | -648.92M | -569.21M | -535.97M |
| Net Income | -186.57M | -454.03M | -707.42M | -606.64M | -569.18M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 1.49B | 1.31B | 1.62B | 1.54B | 1.5B |
| Total Liabilities | 1.22B | 1.17B | 1.19B | 1.18B | 1.24B |
| Total Equity | 275.41M | 140.26M | 432.42M | 346.83M | 255.3M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 1.76B | 1.52B | 1.55B | 1.49B | 1.5B |
| Total Liabilities | 605.18M | 599.84M | 1.19B | 1.22B | 1.24B |
| Total Equity | 1.15B | 922.56M | 352.49M | 275.41M | 255.3M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -474.81M | -190.73M | -267.69M | -334.69M | -414.19M |
| Investing | 168M | 94.44M | 155M | -120.5M | -17.77M |
| Financing | 388.14M | -58k | 384.88M | 396.06M | 399.24M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -132.22M | -338.71M | -380.47M | -474.81M | -414.19M |
| Investing | -179.12M | -195.37M | -291.65M | 168M | -17.77M |
| Financing | 600.27M | 118.55M | 501.21M | 388.14M | 399.24M |
| Market Cap | 3.58B |
| Price to Earnings Ratio | -6.38 |
| Price to Sales Ratio | 6.48 |
| Price to Cash Ratio | 20.9 |
| Price to Book Ratio | 13.84 |
| Dividend Yield | - |
| Shares Outstanding | 92.5M |
| Average Volume (1 week) | 712k |
| Average Volume (1 Month) | 802.93k |
| 52 Week Change | -19.08% |
| 52 Week High | 60.37 |
| 52 Week Low | 37.02 |
| Spread (Intraday) | 11.98 (26.1%) |
| Company Name | Ultragenyx Pharmaceutical Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.ultragenyx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
